Skip to content
Screener

aTyr Pharma ATYR Q1 2025 earnings

Reported May 7, 2025 · Before market open

Revenue-
EPS-$0.17Beat by $0.02
EPS estimate-$0.19

Next report

Nov 5, 2026 (in 3 months)
Revenue estimate$2.5M
EPS estimate-$0.17

Financials

Q1 2025

Income statement

See full
Revenue--100%
Operating income-$15.8M+5.2%
Net income-$14.9M+3.9%
EPS (diluted)-$0.17+26.1%

Balance sheet

See full
Cash & equivalents$10.4M+52.2%
Total debt$13.5M-7.5%
Total equity$75.1M-11.1%
Total assets$97.2M-14.1%

Cash flow

See full
Operating cash flow-$15.4M+31.1%
CapEx--100%
Free cash flow-$15.4M+31.2%

Valuation & ratios

Valuation

as of 03/31/25
See full
Market cap$268.35M—
Enterprise value$271.53M—

Returns & leverage

See full
Return on equity-79.5%+60.6pp
Debt / equity0.2×0.0×
Current ratio7.8×+1.7×

FAQ

When did aTyr Pharma report Q1 2025 earnings?
aTyr Pharma (ATYR) reported Q1 2025 earnings on May 7, 2025 before market open.
What were aTyr Pharma's Q1 2025 revenue and EPS?
aTyr Pharma reported revenue of - and eps of $-0.17 for Q1 2025.
Did aTyr Pharma beat estimates in Q1 2025?
EPS beat the consensus estimate of $-0.19 by $0.02.
How did aTyr Pharma's Q1 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 100.0% from $235.0K a year earlier and eps grew 26.1% from $-0.23.
Where can I find aTyr Pharma's Q1 2025 SEC filings?
You can read the 8-K earnings release (0000950170-25-064413) and the 10-Q periodic report (0000950170-25-065640) directly on SEC EDGAR. The filing index links above go to sec.gov.